


CLAIMS

REPLACED BY
ART 34 AMDT

1. Use of an α -aminoamide of formula (I):



wherein:

A is a $-(\text{CH}_2)_m-$ or $-(\text{CH}_2)_n-\text{X}-$, wherein m is 1 or 2; n is zero, 1 or 2; and X is $-\text{O}-$, $-\text{S}-$ or $-\text{NH}-$;

R is a furyl, thienyl, or pyridyl ring or a phenyl ring, unsubstituted or substituted by one or two substituents independently selected from halogen, hydroxy, C_1 - C_4 alkyl, C_1 - C_3 alkoxy and trifluoromethyl;

R_1 is hydrogen or C_1 - C_3 alkyl;

R_2 is hydrogen or C_1 - C_2 alkyl, unsubstituted or substituted by hydroxy or phenyl; phenyl, unsubstituted or substituted by one or two substituents independently selected from C_1 - C_3 alkyl, halogen, hydroxy, C_1 - C_2 alkoxy or trifluoromethyl;

R_3 is hydrogen or C_1 - C_3 alkyl;

if the case, either as a single isomer, or as a mixture thereof, or a pharmaceutically acceptable derivative thereof;

in the manufacture of a medicament for the treatment of head pain conditions.

2. Use of an α -aminoamide according to claim 1, wherein in formula (I):

A is a group selected from $-\text{CH}_2-\text{CH}_2-$, $-\text{CH}_2-\text{O}-$, $-\text{CH}_2-\text{S}-$, $-\text{CH}_2-\text{CH}_2-\text{O}-$;

R is a phenyl ring, unsubstituted or substituted by one or two substituents independently selected from halogen, C_1 - C_3 alkyl or a methoxy group; or a thienyl ring;

R_1 is hydrogen or C_1 - C_2 alkyl;

R_2 is hydrogen or methyl, unsubstituted or substituted by hydroxy, or phenyl unsubstituted or substituted by C_1 - C_2 alkyl, halogen, hydroxy, methoxy or trifluoromethyl; and

R_3 is hydrogen or C_1 - C_2 alkyl.

3. Use of an α -aminoamide according to claim 1 or 2,

wherein in formula (I):

A is $-\text{CH}_2-\text{O}-$, $-\text{CH}_2-\text{S}-$ or $-\text{CH}_2-\text{CH}_2-$;

R is a phenyl ring, unsubstituted or substituted by one or two halogen atoms;

R_1 is hydrogen;

R_2 is hydrogen or methyl, unsubstituted or substituted by hydroxy or phenyl ring, unsubstituted or substituted by a halogen atom; and

R_3 is hydrogen or methyl.

4. Use of an α -aminoamide according to claim 1, wherein the α -aminoamide is selected from:

2-(4-benzyloxybenzylamino)propanamide;

2-[4-(2-fluorobenzyloxy)benzylamino]propanamide;

2-[4-(2-chlorobenzyloxy)benzylamino]propanamide;

2-[4-(3-fluorobenzyloxy)benzylamino]propanamide;

2-[4-(3-chlorobenzyloxy)benzylamino]propanamide;

2-[4-(4-fluorobenzyloxy)benzylamino]propanamide;

2-[4-(2-fluorobenzyloxy)benzylamino]-N-methyl-propanamide;

2-[4-(3-fluorobenzyloxy)benzylamino]-N-methyl-propanamide;

2-[4-(2-fluorobenzyloxy)benzylamino]-3-hydroxy-propanamide;

2-[4-(3-fluorobenzyloxy)benzylamino]-3-hydroxy-propanamide;

2-(4-benzyloxybenzylamino)-3-hydroxy-N-methylpropanamide;

2-[4-(2-fluorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;

2-[4-(2-chlorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;

2-[4-(3-fluorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;

2-[4-(3-chlorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;

2-(4-(2-thienylmethylenoxy)benzylamino)-propanamide;

2-[4-(2-(3-fluorophenyl)ethyl)benzylamino]-propanamide;

2-[4-benzylthiobenzylamino]-propanamide;

2-[4-benzyloxybenzylamino]-3-phenyl-N-methylpropanamide;

2-[4-benzyloxybenzylamino] N-methylbutanamide;

2-[4-benzyloxybenzylamino]-2-phenyl-acetamide;

2-[4-(2-fluorobenzyloxy)benzylamino]-2-phenyl-acetamide;
2-[4-(3-fluorobenzyloxy)benzylamino]-2-phenyl-acetamide;
2-[4-(3-chlorobenzyloxy)benzylamino]-2-phenyl-acetamide;
2-[4-(3-fluorobenzyloxy)benzylamino]-2-(2-fluorophenyl)-
acetamide;

2-[4-(3-fluorobenzyloxy)benzylamino]-2-(3-fluorophenyl)-
acetamide;

2-[4-(3-chlorobenzyloxy)benzylamino]-2-(3-fluorophenyl)-
acetamide;

if the case, either as a single isomer or as a mixture thereof, or a pharmaceutically acceptable derivative thereof.

5. Use of an α -aminoamide according to any of the previous claims, wherein the α -aminoamide is selected from: (S)-(+)-2-[4-(3-fluorobenzyloxy)benzylamino]-propanamide, (S)-(+)-2-[4-(2-fluorobenzyloxy)benzylamino]-propanamide and (S)-(+)-2-[4-(3-chlorobenzyloxy)benzylamino]-propanamide.

6. Use according to any of the previous claims, wherein the head pain conditions are involving a cerebral vasodilatation mechanism.

7. Use according to any of the previous claims, wherein head pain conditions are both primary and secondary headache disorders.

8. Use according to any of the previous claims, wherein the primary headache disorders derive from the intense pain of acute migraine or cluster headaches or from vascular mechanisms; and the secondary headache disorders derive from infection, metabolic disorders, or other systemic illnesses.

9. Use according to any of the previous claims, wherein head pain conditions include migraine, headache, neuralgia, hemicrania, facial pain and arachnoiditis.

10. Use according to any of the previous claims, wherein migraine is acute, transformed or vascular migraine; headache is acute, cluster, evolutive or tension type headache; neuralgia is trigeminal neuralgia; hemicrania is chronic paroxysmal hemicrania.

11. A method for the treatment of head pain conditions in a

mammal in need thereof comprising administering to the mammal a therapeutically effective dose of at least one α -aminoamide of formula (I) as defined in any of claims 1 to 5.

12. A method according to the previous claim, wherein the mammal is administered a dose of the α -aminoamide of formula (I) as defined in any of claims 1 to 5 which ranges from about 0.05 to 20 mg/kg body weight per day.

13. A method according to claim 11 or 12, wherein the mammal is administered a dose of the α -aminoamide of formula (I) as defined in any of claims 1 to 5 which ranges from about 0.5 to 10 mg/kg day.

14. A method according to any of claims from 11 to 13, wherein the mammal is administered a dose of the α -aminoamide of formula (I) as defined in any of claims 1 to 5 which ranges from about 0.5 to 5 mg/kg day.

15. A method according to any of claims from 11 to 14, wherein the head pain conditions are as defined in any of claims 6 to 10.